اعلان اعلى المواضيع
Dexamethasone
Health care facilities have announced news that it is a turning point and a people of hope for all who are suffering from the emerging epidemic. Usual care.
The study found that dexamethasone reduced the death rate by a third in patients with a very serious disease and those who breathe and fifth among patients treated with oxygen, and compared the results with a control group receiving regular care. .
However, dexamethasone showed no benefit in patients with mild or moderate symptoms of Covid-19 who did not need respiratory assistance.
Random clinical trials were conducted in the United Kingdom to assess all possible treatments, including dexamethasone, cetizumab (Actimra), azithromycin plasma retreator, lupinavir / ritonavir (caletra); Hydroxychloroquine was also tested, but the experiment was stopped after showing no benefit.
"Dexamethasone is the first drug to show promising results in patients with severe COVID-19 infection," lead researcher Peter Hurby, PhD from Oxford University, said in a group statement. Therefore, dexamethasone should now become a standard of care for these patients and describe fugitive dexamethasone as "inexpensive, available and can be used immediately to save lives around the world." "
Sir Patrick Valance, the UK's leading scientific advisor, described the news as an "innovative development" in the battle against COVID-19.
In the experiment to date, 2,104 patients were randomized to receive 6 mg of dexamethasone intravenously over 10 days, compared to 4,321 patients who received regular care.
In the usual care group, the 28-day death rate was 41% higher in patients requiring ventilator and the death rate was 25% for those who only needed oxygen and 13% for those who did not need and did not need any support at all. respiratory.
The researchers said they are preliminary results and they will work to release all details soon.
ادسنس وسط المقال
